{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:52:07Z","timestamp":1769273527256,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["angiogenesis and tumour grant"],"award-info":[{"award-number":["angiogenesis and tumour grant"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00262-019-02317-9","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:13:24Z","timestamp":1551658404000},"page":"871-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-3753","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Quillien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine F.","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Gey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Avril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floraly","family":"Sejalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Campillo-Gimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Vauleon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"2317_CR1","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"2317_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745","journal-title":"J Clin Oncol"},{"key":"2317_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943\u2013953. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6","journal-title":"Lancet Oncol"},{"key":"2317_CR4","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954\u20131963. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"key":"2317_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejca.2016.11.002","volume":"70","author":"P Rana","year":"2017","unstructured":"Rana P, Pritchard KI, Kerbel R (2017) Plasma vascular endothelial growth factor as a predictive biomarker: door closed? Eur J Cancer 70:143\u2013145. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.11.002","journal-title":"Eur J Cancer"},{"key":"2317_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/neuonc\/nov288","volume":"18","author":"P Baumgarten","year":"2016","unstructured":"Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bahr O, Mader L, Goeppert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN, Mittelbronn M (2016) Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol 18:173\u2013183. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nov288","journal-title":"Neuro Oncol"},{"key":"2317_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/0008-5472.CAN-15-0776","volume":"76","author":"L Erdem-Eraslan","year":"2016","unstructured":"Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Bottcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ (2016) Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial. Cancer Res 76:525\u2013534. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0776","journal-title":"Cancer Res"},{"key":"2317_CR8","doi-asserted-by":"publisher","first-page":"282815","DOI":"10.1155\/2014\/282815","volume":"2014","author":"J Laffaire","year":"2014","unstructured":"Laffaire J, Di Stefano AL, Chinot O, Idbaih A, Gallego Perez-Larraya J, Marie Y, Vintonenko N, Boisselier B, Farina P, Delattre JY, Figarella-Branger D, Honnorat J, Sanson M, Ducray F (2014) An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas. Biomed Res Int 2014:282815. \n                    https:\/\/doi.org\/10.1155\/2014\/282815","journal-title":"Biomed Res Int"},{"key":"2317_CR9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.molonc.2016.06.004","volume":"10","author":"J Hayes","year":"2016","unstructured":"Hayes J, Thygesen H, Gregory W, Westhead DR, French PJ, Van Den Bent MJ, Lawler SE, Short SC (2016) A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Mol Oncol 10:1296\u20131304. \n                    https:\/\/doi.org\/10.1016\/j.molonc.2016.06.004","journal-title":"Mol Oncol"},{"key":"2317_CR10","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.molonc.2016.05.005","volume":"10","author":"T Urup","year":"2016","unstructured":"Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U (2016) Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Mol Oncol 10:1160\u20131168. \n                    https:\/\/doi.org\/10.1016\/j.molonc.2016.05.005","journal-title":"Mol Oncol"},{"key":"2317_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","volume":"11","author":"LB Rivera","year":"2015","unstructured":"Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G (2015) Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep 11:577\u2013591. \n                    https:\/\/doi.org\/10.1016\/j.celrep.2015.03.055","journal-title":"Cell Rep"},{"key":"2317_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539\u2013549. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2325","journal-title":"Cancer Res"},{"key":"2317_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/CJI.0b013e3181f4c208","volume":"33","author":"O Adotevi","year":"2010","unstructured":"Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V, Mejean A, Fridman WH, Oudard S, Tartour E (2010) A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 33:991\u2013998","journal-title":"J Immunother"},{"key":"2317_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00262-016-1836-3","volume":"65","author":"S Du Four","year":"2016","unstructured":"Du Four S, Maenhout SK, Benteyn D, De Keersmaecker B, Duerinck J, Thielemans K, Neyns B, Aerts JL (2016) Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. Cancer Immunol Immunother 65:727\u2013740. \n                    https:\/\/doi.org\/10.1007\/s00262-016-1836-3","journal-title":"Cancer Immunol Immunother"},{"key":"2317_CR15","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/brain\/aww046","volume":"139","author":"KL Pitter","year":"2016","unstructured":"Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D (2016) Corticosteroids compromise survival in glioblastoma. Brain 139:1458\u20131471. \n                    https:\/\/doi.org\/10.1093\/brain\/aww046","journal-title":"Brain"},{"key":"2317_CR16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/01.CIR.98.21.2307","volume":"98","author":"M Nakagawa","year":"1998","unstructured":"Nakagawa M, Terashima T, D\u2019Yachkova Y, Bondy GP, Hogg JC, van Eeden SF (1998) Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 98:2307\u20132313","journal-title":"Circulation"},{"key":"2317_CR17","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1182\/blood-2015-03-631572","volume":"126","author":"S Massena","year":"2015","unstructured":"Massena S, Christoffersson G, Vagesjo E, Seignez C, Gustafsson K, Binet F, Herrera Hidalgo C, Giraud A, Lomei J, Westrom S, Shibuya M, Claesson-Welsh L, Gerwins P, Welsh M, Kreuger J, Phillipson M (2015) Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans. Blood 126:2016\u20132026. \n                    https:\/\/doi.org\/10.1182\/blood-2015-03-631572","journal-title":"Blood"},{"key":"2317_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-13-1279","volume":"20","author":"J Liang","year":"2014","unstructured":"Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF (2014) Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res 20:187\u2013198. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1279","journal-title":"Clin Cancer Res"},{"key":"2317_CR19","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1158\/1078-0432.CCR-11-1107","volume":"17","author":"TR Sippel","year":"2011","unstructured":"Sippel TR, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-DeMasters BK, Waziri A (2011) Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res 17:6992\u20137002. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1107","journal-title":"Clin Cancer Res"},{"key":"2317_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood-2016-04-713206","volume":"129","author":"O Marini","year":"2017","unstructured":"Marini O, Costa S, Bevilacqua D, Calzetti F, Tamassia N, Spina C, De Sabata D, Tinazzi E, Lunardi C, Scupoli MT, Cavallini C, Zoratti E, Tinazzi I, Marchetta A, Vassanelli A, Cantini M, Gandini G, Ruzzenente A, Guglielmi A, Missale F, Vermi W, Tecchio C, Cassatella MA, Scapini P (2017) Mature CD10(+) and immature CD10(\u2212) neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood 129: 1343\u20131356. \n                    https:\/\/doi.org\/10.1182\/blood-2016-04-713206","journal-title":"Blood"},{"key":"2317_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/neuonc\/now034","volume":"18","author":"PR Gielen","year":"2016","unstructured":"Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Bossman SA, Ter Laan M, Wesseling P, Adema GJ (2016) Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8\/9 and arginase and suppress T cell function. Neuro Oncol 18:1253\u20131264. \n                    https:\/\/doi.org\/10.1093\/neuonc\/now034","journal-title":"Neuro Oncol"},{"key":"2317_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/neuonc\/nor042","volume":"13","author":"B Raychaudhuri","year":"2011","unstructured":"Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J (2011) Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13:591\u2013599. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nor042","journal-title":"Neuro Oncol"},{"key":"2317_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-017-2641-3","volume":"136","author":"M Lopes","year":"2018","unstructured":"Lopes M, Carvalho B, Vaz R, Linhares P (2018) Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol 136:173\u2013180. \n                    https:\/\/doi.org\/10.1007\/s11060-017-2641-3","journal-title":"J Neurooncol"},{"key":"2317_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11060-017-2395-y","volume":"132","author":"M Mason","year":"2017","unstructured":"Mason M, Maurice C, McNamara MG, Tieu MT, Lwin Z, Millar BA, Menard C, Laperriere N, Milosevic M, Atenafu EG, Mason W, Chung C (2017) Neutrophil\u2013lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J Neurooncol 132:463\u2013471. \n                    https:\/\/doi.org\/10.1007\/s11060-017-2395-y","journal-title":"J Neurooncol"},{"key":"2317_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12885-015-1629-7","volume":"15","author":"S Han","year":"2015","unstructured":"Han S, Liu Y, Li Q, Li Z, Hou H, Wu A (2015) Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 15:617. \n                    https:\/\/doi.org\/10.1186\/s12885-015-1629-7","journal-title":"BMC Cancer"},{"key":"2317_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11060-013-1240-1","volume":"115","author":"GA Alexiou","year":"2013","unstructured":"Alexiou GA, Vartholomatos E, Voulgaris S (2013) Prognostic value of neutrophil-to-lymphocyte ratio in patients with glioblastoma. J Neurooncol 115:521\u2013522. \n                    https:\/\/doi.org\/10.1007\/s11060-013-1240-1","journal-title":"J Neurooncol"},{"key":"2317_CR27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10898","author":"A Bertaut","year":"2016","unstructured":"Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangere V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F (2016) Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget. \n                    https:\/\/doi.org\/10.18632\/oncotarget.10898","journal-title":"Oncotarget"},{"key":"2317_CR28","doi-asserted-by":"publisher","first-page":"61916","DOI":"10.18632\/oncotarget.11322","volume":"7","author":"V Quillien","year":"2016","unstructured":"Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D (2016) Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. Oncotarget 7:61916\u201361929. \n                    https:\/\/doi.org\/10.18632\/oncotarget.11322","journal-title":"Oncotarget"},{"key":"2317_CR29","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1200\/JCO.2009.23.0680","volume":"27","author":"C Badoual","year":"2009","unstructured":"Badoual C, Hans S, Fridman WH, Brasnu D, Erdman S, Tartour E (2009) Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 27:e5\u2013e6 (author reply e7). \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.0680","journal-title":"J Clin Oncol"},{"key":"2317_CR30","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang SJ (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5:15179. \n                    https:\/\/doi.org\/10.1038\/srep15179","journal-title":"Sci Rep"},{"key":"2317_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298\u2013306. \n                    https:\/\/doi.org\/10.1038\/nrc3245","journal-title":"Nat Rev Cancer"},{"key":"2317_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11060-013-1314-0","volume":"116","author":"Q Yue","year":"2014","unstructured":"Yue Q, Zhang X, Ye HX, Wang Y, Du ZG, Yao Y, Mao Y (2014) The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol 116:251\u2013259. \n                    https:\/\/doi.org\/10.1007\/s11060-013-1314-0","journal-title":"J Neurooncol"},{"key":"2317_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/neuonc\/nou363","volume":"17","author":"AA Thomas","year":"2015","unstructured":"Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, Olek S, Schwachula T, Rhodes CH, Gui J, Tafe LJ, Tsongalis GJ, Lefferts JA, Wishart H, Kleen J, Miller M, Whipple CA, de Abreu FB, Ernstoff MS, Fadul CE (2015) Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol 17:801\u2013809. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nou363","journal-title":"Neuro Oncol"},{"key":"2317_CR34","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1038\/bjc.2014.162","volume":"110","author":"S Han","year":"2014","unstructured":"Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, Jiang T, Wu A (2014) Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 110:2560\u20132568. \n                    https:\/\/doi.org\/10.1038\/bjc.2014.162","journal-title":"Br J Cancer"},{"key":"2317_CR35","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1002\/ijc.28937","volume":"135","author":"KS Voo","year":"2014","unstructured":"Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS (2014) Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135:2834\u20132846. \n                    https:\/\/doi.org\/10.1002\/ijc.28937","journal-title":"Int J Cancer"},{"key":"2317_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/ejh.12144","volume":"91","author":"M Glowala-Kosinska","year":"2013","unstructured":"Glowala-Kosinska M, Chwieduk A, Nieckula J, Sadus-Wojciechowska M, Grosicki S, Rusin A, Nowara E, Giebel S (2013) Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol 91:122\u2013128. \n                    https:\/\/doi.org\/10.1111\/ejh.12144","journal-title":"Eur J Haematol"},{"key":"2317_CR37","doi-asserted-by":"publisher","first-page":"39247","DOI":"10.1038\/srep39247","volume":"6","author":"A Kotsakis","year":"2016","unstructured":"Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK (2016) Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep 6:39247. \n                    https:\/\/doi.org\/10.1038\/srep39247","journal-title":"Sci Rep"},{"key":"2317_CR38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-017-2477-x","volume":"133","author":"RJ Diaz","year":"2017","unstructured":"Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ (2017) The role of bevacizumab in the treatment of glioblastoma. J Neurooncol 133:455\u2013467. \n                    https:\/\/doi.org\/10.1007\/s11060-017-2477-x","journal-title":"J Neurooncol"},{"key":"2317_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/neuonc\/not226","volume":"16","author":"E Tabouret","year":"2014","unstructured":"Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L, Chinot O (2014) Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol 16:392\u2013399. \n                    https:\/\/doi.org\/10.1093\/neuonc\/not226","journal-title":"Neuro Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02317-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02317-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02317-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T19:23:23Z","timestamp":1583177003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02317-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02317-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"10 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Trial number for the prospective study: NCT01836536\/clinical trial.gov. The prospective protocol was approved by the Rennes Medical Ethics Committee and patients gave written informed consent to the use of their materials for research purposes prior to treatment (reference 12\/01-834). For the retrospective cohorts, patients had given their non-opposition for the use of their anonymous clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}}]}}